SAN DIEGO – September 5, 2012 – OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse and NeoPulse technologies to treat solid tumor cancers, received a new Method of Use and Device patent (Patent Application No. 200780014313.0, “Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection”) for the OncoSec Medical System (OMS) electroporation device platform from the State Intellectual Property Office of the People’s Republic of China. The issuance of this patent has the potential to expand OncoSec’s commercial opportunities for minimally invasive and surgical procedures to treat solid tumors in a very large market such as China.
Punit Dhillon, OncoSec’s President and CEO, commented, “The issuance of this patent is significant, because the Chinese authorities have given the company patent approval for our claims regarding the OMS electroporation device itself, as well as the method of use. These are broad claims, wherein OncoSec now has the ability to deliver various therapeutic agents through its electroporation device, including bleomycin and DNA IL-12, as well as to treat tumors with these agents following surgical resection. Thus, this patent will act as a part of the company’s core strategy as we continue to develop and build our commercialization strategy in China, one of the largest emerging oncology markets.”
Numerous research studies have concluded that cancer has now become a leading cause of mortality in China, representing 25 percent of all deaths in urban areas and 21 percent in rural areas. Moreover, cancer mortality in China has been increasing rapidly and continuously during the past three decades, which indicates a significant need for novel therapies.
ImmunoPulse and NeoPulse are investigational therapies being evaluated to reduce the rate of cancer recurrence while minimizing quality-of-life side effects. These therapeutic approaches, as potential adjuncts to surgery, involve injecting the tumor with an anti-cancer agent, followed by electroporation to open up the cell membrane, which helps significantly increase the uptake of the agent. This approach has been shown to selectively kill cancer cells that may exist in the neighboring tissue, which may result in a reduced rate of recurrence and has the potential to complement standard-of-care surgical procedures.